Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24783511,m/,"The detection used the transitions of protonated molecules at m/z 234.2-->84.1 for MPH and m/z 260.3-->183.1 for propranolol (IS), separately.",[LC-MS/MS assay of methylphenidate: stability and pharmacokinetics in human]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783511/),,234.2,1575,DB00422,Methylphenidate
,24783511,m/z,"The detection used the transitions of protonated molecules at m/z 234.2-->84.1 for MPH and m/z 260.3-->183.1 for propranolol (IS), separately.",[LC-MS/MS assay of methylphenidate: stability and pharmacokinetics in human]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783511/),,260.3,1576,DB00422,Methylphenidate
,24783511,m/z,"The detection used the transitions of protonated molecules at m/z 234.2-->84.1 for MPH and m/z 260.3-->183.1 for propranolol (IS), separately.",[LC-MS/MS assay of methylphenidate: stability and pharmacokinetics in human]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783511/),,183.1,1577,DB00422,Methylphenidate
,32776159,dose-normalized Cmax,"Mean dose-normalized Cmax and area under the curve to the last measurable observation (AUC0-t) values were similar across dose groups, ranging from 0.67 ng/mL/mg (MPH 15 mg) to 0.81 ng/mL/mg (MPH 10 mg) for Cmax/dose, and from 7.80 h × ng/mL/mg (MPH 20 mg) to 8.92 h × ng/mL/mg (MPH 10 mg) for AUC0-t/dose.",A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32776159/),[ng] / [mg·ml],0.67,3524,DB00422,Methylphenidate
,32776159,area under the curve to the last measurable observation (AUC0-t),"Mean dose-normalized Cmax and area under the curve to the last measurable observation (AUC0-t) values were similar across dose groups, ranging from 0.67 ng/mL/mg (MPH 15 mg) to 0.81 ng/mL/mg (MPH 10 mg) for Cmax/dose, and from 7.80 h × ng/mL/mg (MPH 20 mg) to 8.92 h × ng/mL/mg (MPH 10 mg) for AUC0-t/dose.",A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32776159/),[ng] / [mg·ml],0.81,3525,DB00422,Methylphenidate
,32776159,AUC0-t/dose,"Mean dose-normalized Cmax and area under the curve to the last measurable observation (AUC0-t) values were similar across dose groups, ranging from 0.67 ng/mL/mg (MPH 15 mg) to 0.81 ng/mL/mg (MPH 10 mg) for Cmax/dose, and from 7.80 h × ng/mL/mg (MPH 20 mg) to 8.92 h × ng/mL/mg (MPH 10 mg) for AUC0-t/dose.",A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32776159/),[h·ng] / [mg·ml],7.80,3526,DB00422,Methylphenidate
,32776159,AUC0-t/dose,"Mean dose-normalized Cmax and area under the curve to the last measurable observation (AUC0-t) values were similar across dose groups, ranging from 0.67 ng/mL/mg (MPH 15 mg) to 0.81 ng/mL/mg (MPH 10 mg) for Cmax/dose, and from 7.80 h × ng/mL/mg (MPH 20 mg) to 8.92 h × ng/mL/mg (MPH 10 mg) for AUC0-t/dose.",A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32776159/),[h·ng] / [mg·ml],8.92,3527,DB00422,Methylphenidate
,32776159,CL,"Mean CL, normalized for body weight, was constant for all dose groups, ranging from 4.88 L/h/kg to 5.80 L/h/kg.",A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32776159/),[l] / [h·kg],4.88,3528,DB00422,Methylphenidate
,32776159,CL,"Mean CL, normalized for body weight, was constant for all dose groups, ranging from 4.88 L/h/kg to 5.80 L/h/kg.",A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32776159/),[l] / [h·kg],5.80,3529,DB00422,Methylphenidate
,32776159,time to Cmax,"Median time to Cmax ranged from 2.00 to 3.00 h post-dose, and overall, dose-normalized Cmax concentrations indicated greater systemic exposures of MPH-MLR in preschool children aged 4 to < 6 years compared with children aged 6-11 years.",A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32776159/),h,2.00 to 3.00,3530,DB00422,Methylphenidate
,10654657,plasma half-life,"The plasma half-life of these compounds in children is approximately 5 h, with an onset of therapeutic action within a half-hour, and peak action at 1-3 h.",Clinical psychopharmacology of AD/HD: implications for animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10654657/),h,5,6446,DB00422,Methylphenidate
,2095405,recovery,The recovery (MPD + the metabolite) in urine for 24 h was 16-18% in the range of the oral doses.,Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095405/),%,16-18,8050,DB00422,Methylphenidate
,26751592,flow,"Chiral separation was performed on an Astec Chirobiotic V2 column (5μm, 250×2.1mm) with isocratic elution using methanol containing 0.003% ammonium acetate (w/v) and 0.003% trifluoroacetic acid (v/v) at a flow of 0.3mL/min.","Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751592/),[ml] / [min],0.3,17593,DB00422,Methylphenidate
,26751592,Extraction recoveries,"Extraction recoveries were 55-62% for d-threo-MPH, 54-60% for l-threo-MPH, 55-60% for d-threo-EPH, 53-57% for l-threo-EPH and 25-30% for d,l-threo-RA.","Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751592/),%,55-62,17594,DB00422,Methylphenidate
,26751592,Extraction recoveries,"Extraction recoveries were 55-62% for d-threo-MPH, 54-60% for l-threo-MPH, 55-60% for d-threo-EPH, 53-57% for l-threo-EPH and 25-30% for d,l-threo-RA.","Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751592/),%,54-60,17595,DB00422,Methylphenidate
,26751592,Extraction recoveries,"Extraction recoveries were 55-62% for d-threo-MPH, 54-60% for l-threo-MPH, 55-60% for d-threo-EPH, 53-57% for l-threo-EPH and 25-30% for d,l-threo-RA.","Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751592/),%,55-60,17596,DB00422,Methylphenidate
,26751592,Extraction recoveries,"Extraction recoveries were 55-62% for d-threo-MPH, 54-60% for l-threo-MPH, 55-60% for d-threo-EPH, 53-57% for l-threo-EPH and 25-30% for d,l-threo-RA.","Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751592/),%,53-57,17597,DB00422,Methylphenidate
,26751592,Extraction recoveries,"Extraction recoveries were 55-62% for d-threo-MPH, 54-60% for l-threo-MPH, 55-60% for d-threo-EPH, 53-57% for l-threo-EPH and 25-30% for d,l-threo-RA.","Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751592/),%,25-30,17598,DB00422,Methylphenidate
greater,12954808,time to peak DAT occupancy,The time to peak DAT occupancy for the cocaine analogs was greater than 30 min.,The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954808/),min,30,21077,DB00422,Methylphenidate
,10391421,weight,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22460,DB00422,Methylphenidate
,10391421,weight-,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22461,DB00422,Methylphenidate
,10391421,dose-normalized serum concentrations,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22462,DB00422,Methylphenidate
,10391421,dose-normalized serum concentrations,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],39.02,22463,DB00422,Methylphenidate
,10391421,clearance,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[l] / [kg],0.690,22464,DB00422,Methylphenidate
,10391421,clearance,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[l] / [kg],0.613,22465,DB00422,Methylphenidate
,18343243,Tmax,The mean Tmax for the 2 formulations was 3.71 (2.03) and 4.96 (2.56) hours.,Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343243/),h,3.71,38603,DB00422,Methylphenidate
,18343243,Tmax,The mean Tmax for the 2 formulations was 3.71 (2.03) and 4.96 (2.56) hours.,Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343243/),h,4.96,38604,DB00422,Methylphenidate
,20814325,Accumulation,"Accumulation of d-MPH was 34% in children and 57% in adolescents after multiple fixed doses of MTS for 7 days and 76% and 94%, respectively, after 28 days of dosing.",Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814325/),%,34,40276,DB00422,Methylphenidate
,20814325,Accumulation,"Accumulation of d-MPH was 34% in children and 57% in adolescents after multiple fixed doses of MTS for 7 days and 76% and 94%, respectively, after 28 days of dosing.",Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814325/),%,57,40277,DB00422,Methylphenidate
,20814325,Accumulation,"Accumulation of d-MPH was 34% in children and 57% in adolescents after multiple fixed doses of MTS for 7 days and 76% and 94%, respectively, after 28 days of dosing.",Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814325/),%,76,40278,DB00422,Methylphenidate
,20814325,Accumulation,"Accumulation of d-MPH was 34% in children and 57% in adolescents after multiple fixed doses of MTS for 7 days and 76% and 94%, respectively, after 28 days of dosing.",Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814325/),%,94,40279,DB00422,Methylphenidate
,20814325,accumulation,"After 7 days of OROS MPH dosing, accumulation was 16% in children and 19% in adolescents; fixed doses of OROS MPH were not studied beyond 7 days.",Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814325/),%,16,40280,DB00422,Methylphenidate
,20814325,accumulation,"After 7 days of OROS MPH dosing, accumulation was 16% in children and 19% in adolescents; fixed doses of OROS MPH were not studied beyond 7 days.",Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814325/),%,19,40281,DB00422,Methylphenidate
,26729760,AUC0-∞ ratio,"The maximum d-MPH plasma concentration (Cmax) for dl-MPH was also significantly lower for dl-MPH (P < 0.05; CI, 1.02-1.19), whereas the AUC0-∞ ratio of 0.89 was not significantly different (P = 0.21; CI, 0.98-1.13).",Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26729760/),,0.89,41815,DB00422,Methylphenidate
,10820132,area under the concentration versus time curve,"The mean (+/-S.D.) area under the concentration versus time curve for ethylphenidate was 1.2 +/- 0.7 ng/ml/h, representing 2.3 +/- 1.3% that of methylphenidate (48 +/- 12 ng/ml/h).",Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820132/),[ng] / [h·ml],1.2,56485,DB00422,Methylphenidate
,10820132,area under the concentration versus time curve,"The mean (+/-S.D.) area under the concentration versus time curve for ethylphenidate was 1.2 +/- 0.7 ng/ml/h, representing 2.3 +/- 1.3% that of methylphenidate (48 +/- 12 ng/ml/h).",Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820132/),[ng] / [h·ml],48,56486,DB00422,Methylphenidate
,20043136,occupancy,"At 10 h, plasma d-MPH levels were lower (3.8+/-1.2 vs. 5.2+/-2.0) and brain DAT occupancy was lower (34.8+/-12.9 vs. 44.3+/-11.8) for DBDS-MPH than OROS-MPH.",A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20043136/),,34.8,58697,DB00422,Methylphenidate
,20043136,occupancy,"At 10 h, plasma d-MPH levels were lower (3.8+/-1.2 vs. 5.2+/-2.0) and brain DAT occupancy was lower (34.8+/-12.9 vs. 44.3+/-11.8) for DBDS-MPH than OROS-MPH.",A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20043136/),,44.3,58698,DB00422,Methylphenidate
,28628269,area under the plasma concentration-vs-time curve (AUC)0-t,"When MEROS 60 mg was administered under fed conditions compared with fasting conditions, the exposure of methylphenidate (d enantiomer) was higher, with a mean area under the plasma concentration-vs-time curve (AUC)0-t of 160.2 ng·h/mL vs 140.4 ng·h/mL, and a mean AUC0-inf of 163.2 ng·h/mL vs 143.7 ng·h/mL, respectively.",Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28628269/),[h·ng] / [ml],160.2,58767,DB00422,Methylphenidate
,28628269,area under the plasma concentration-vs-time curve (AUC)0-t,"When MEROS 60 mg was administered under fed conditions compared with fasting conditions, the exposure of methylphenidate (d enantiomer) was higher, with a mean area under the plasma concentration-vs-time curve (AUC)0-t of 160.2 ng·h/mL vs 140.4 ng·h/mL, and a mean AUC0-inf of 163.2 ng·h/mL vs 143.7 ng·h/mL, respectively.",Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28628269/),[h·ng] / [ml],140.4,58768,DB00422,Methylphenidate
,28628269,AUC0-inf,"When MEROS 60 mg was administered under fed conditions compared with fasting conditions, the exposure of methylphenidate (d enantiomer) was higher, with a mean area under the plasma concentration-vs-time curve (AUC)0-t of 160.2 ng·h/mL vs 140.4 ng·h/mL, and a mean AUC0-inf of 163.2 ng·h/mL vs 143.7 ng·h/mL, respectively.",Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28628269/),[h·ng] / [ml],163.2,58769,DB00422,Methylphenidate
,28628269,AUC0-inf,"When MEROS 60 mg was administered under fed conditions compared with fasting conditions, the exposure of methylphenidate (d enantiomer) was higher, with a mean area under the plasma concentration-vs-time curve (AUC)0-t of 160.2 ng·h/mL vs 140.4 ng·h/mL, and a mean AUC0-inf of 163.2 ng·h/mL vs 143.7 ng·h/mL, respectively.",Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28628269/),[h·ng] / [ml],143.7,58770,DB00422,Methylphenidate
,533578,apparent plasma half life,2 It is indicated that the drug is metabolized to ritalinic acid with an apparent plasma half life of 2.5 h.,Pharmacokinetics of methylphenidate in hyperkinetic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/533578/),h,2.5,69322,DB00422,Methylphenidate
,1403717,d:l ratio,"By contrast, after intravenous administration of MPH, the d:l ratio changed progressively from 1.16 in the 0-2-h urine sample to 9.06 in the 12-16-h sample.",Stereoselective urinary pharmacokinetics of dl-threo-methylphenidate and its major metabolite in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403717/),,1.16,69394,DB00422,Methylphenidate
,1403717,d:l ratio,"By contrast, after intravenous administration of MPH, the d:l ratio changed progressively from 1.16 in the 0-2-h urine sample to 9.06 in the 12-16-h sample.",Stereoselective urinary pharmacokinetics of dl-threo-methylphenidate and its major metabolite in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403717/),,9.06,69395,DB00422,Methylphenidate
,2621579,areas under the plasma level time curves,Mean areas under the plasma level time curves were 132.78 +/- 92.47 ng.h/mL for d-methylphenidate and 12.73 +/- 7.37 ng.h/mL for l-methylphenidate.,Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621579/),[h·ng] / [ml],132.78,70854,DB00422,Methylphenidate
,2621579,areas under the plasma level time curves,Mean areas under the plasma level time curves were 132.78 +/- 92.47 ng.h/mL for d-methylphenidate and 12.73 +/- 7.37 ng.h/mL for l-methylphenidate.,Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621579/),[h·ng] / [ml],12.73,70855,DB00422,Methylphenidate
,12973820,t(max(0-4)),"In all three treatment groups, methylphenidate was rapidly absorbed with an initial average t(max(0-4)) of 1.3-2.4 h and an average peak plasma concentration [C(max(abs))] of 14.4-15.2 ng/ml.",Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973820/),h,1.3-2.4,72198,DB00422,Methylphenidate
,12973820,peak plasma concentration [C(max(abs))],"In all three treatment groups, methylphenidate was rapidly absorbed with an initial average t(max(0-4)) of 1.3-2.4 h and an average peak plasma concentration [C(max(abs))] of 14.4-15.2 ng/ml.",Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973820/),[ng] / [ml],14.4-15.2,72199,DB00422,Methylphenidate
,15015904,time to maximum,"Both the plasma concentrations and behavioural effects of methylphenidate demonstrate a time to maximum of between 1 and 3 hours, with the maximum behavioural effects occurring when the plasma concentrations are increasing.",Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15015904/),h,1 and 3,80800,DB00422,Methylphenidate
,7214694,volume of distribution,"The study yielded ranges for volume of distribution, elimination half-life, and total body clearance of 5.0-6.8 L/kg, 1.6-2.7 hours, and 1.4-2.9 L/kg-hr respectively.",Gas chromatographic/mass spectrometric analysis of methylphenidate (ritalin) in serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214694/),[l] / [kg],5.0-6.8,82202,DB00422,Methylphenidate
,7214694,elimination half-life,"The study yielded ranges for volume of distribution, elimination half-life, and total body clearance of 5.0-6.8 L/kg, 1.6-2.7 hours, and 1.4-2.9 L/kg-hr respectively.",Gas chromatographic/mass spectrometric analysis of methylphenidate (ritalin) in serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214694/),h,1.6-2.7,82203,DB00422,Methylphenidate
,7214694,total body clearance,"The study yielded ranges for volume of distribution, elimination half-life, and total body clearance of 5.0-6.8 L/kg, 1.6-2.7 hours, and 1.4-2.9 L/kg-hr respectively.",Gas chromatographic/mass spectrometric analysis of methylphenidate (ritalin) in serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214694/),[l] / [kg-hr],1.4-2.9,82204,DB00422,Methylphenidate
,21904089,weight-adjusted maximum plasma concentration (Cmax),"Mean values of dose and body weight-adjusted maximum plasma concentration (Cmax) (23.8, 22.3, 22.1, 25.7 [ng/mL]/mg) and area under the concentration-time curve (AUC) (208, 199, 239, 210 [hr·ng/mL]/[mg/kg]) were similar among all age/dose groups, suggesting dose proportionality and a similar rate and extent of absorption in children and adolescents.","Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904089/),[ng] / [mg·ml]],23.8,86906,DB00422,Methylphenidate
,21904089,weight-adjusted maximum plasma concentration (Cmax),"Mean values of dose and body weight-adjusted maximum plasma concentration (Cmax) (23.8, 22.3, 22.1, 25.7 [ng/mL]/mg) and area under the concentration-time curve (AUC) (208, 199, 239, 210 [hr·ng/mL]/[mg/kg]) were similar among all age/dose groups, suggesting dose proportionality and a similar rate and extent of absorption in children and adolescents.","Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904089/),[ng] / [mg·ml]],22.3,86907,DB00422,Methylphenidate
,21904089,weight-adjusted maximum plasma concentration (Cmax),"Mean values of dose and body weight-adjusted maximum plasma concentration (Cmax) (23.8, 22.3, 22.1, 25.7 [ng/mL]/mg) and area under the concentration-time curve (AUC) (208, 199, 239, 210 [hr·ng/mL]/[mg/kg]) were similar among all age/dose groups, suggesting dose proportionality and a similar rate and extent of absorption in children and adolescents.","Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904089/),[ng] / [mg·ml]],22.1,86908,DB00422,Methylphenidate
,21904089,weight-adjusted maximum plasma concentration (Cmax),"Mean values of dose and body weight-adjusted maximum plasma concentration (Cmax) (23.8, 22.3, 22.1, 25.7 [ng/mL]/mg) and area under the concentration-time curve (AUC) (208, 199, 239, 210 [hr·ng/mL]/[mg/kg]) were similar among all age/dose groups, suggesting dose proportionality and a similar rate and extent of absorption in children and adolescents.","Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904089/),[ng] / [mg·ml]],25.7,86909,DB00422,Methylphenidate
,21904089,area under the concentration-time curve (AUC),"Mean values of dose and body weight-adjusted maximum plasma concentration (Cmax) (23.8, 22.3, 22.1, 25.7 [ng/mL]/mg) and area under the concentration-time curve (AUC) (208, 199, 239, 210 [hr·ng/mL]/[mg/kg]) were similar among all age/dose groups, suggesting dose proportionality and a similar rate and extent of absorption in children and adolescents.","Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904089/),[h·ng] / [[mg·kg·ml]],208,86910,DB00422,Methylphenidate
,21904089,area under the concentration-time curve (AUC),"Mean values of dose and body weight-adjusted maximum plasma concentration (Cmax) (23.8, 22.3, 22.1, 25.7 [ng/mL]/mg) and area under the concentration-time curve (AUC) (208, 199, 239, 210 [hr·ng/mL]/[mg/kg]) were similar among all age/dose groups, suggesting dose proportionality and a similar rate and extent of absorption in children and adolescents.","Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904089/),[h·ng] / [[mg·kg·ml]],199,86911,DB00422,Methylphenidate
,21904089,area under the concentration-time curve (AUC),"Mean values of dose and body weight-adjusted maximum plasma concentration (Cmax) (23.8, 22.3, 22.1, 25.7 [ng/mL]/mg) and area under the concentration-time curve (AUC) (208, 199, 239, 210 [hr·ng/mL]/[mg/kg]) were similar among all age/dose groups, suggesting dose proportionality and a similar rate and extent of absorption in children and adolescents.","Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904089/),[h·ng] / [[mg·kg·ml]],239,86912,DB00422,Methylphenidate
,21904089,area under the concentration-time curve (AUC),"Mean values of dose and body weight-adjusted maximum plasma concentration (Cmax) (23.8, 22.3, 22.1, 25.7 [ng/mL]/mg) and area under the concentration-time curve (AUC) (208, 199, 239, 210 [hr·ng/mL]/[mg/kg]) were similar among all age/dose groups, suggesting dose proportionality and a similar rate and extent of absorption in children and adolescents.","Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21904089/),[h·ng] / [[mg·kg·ml]],210,86913,DB00422,Methylphenidate
,28087982,AUC,"Median AUC of d-methylphenidate was significantly larger in the group carrying the 143E allele (53.3 ng ml-1 h-1 , range 38.6-93.9) than in the control group (21.4 ng ml-1 h-1 , range 15.7-34.9) (P < 0.0001).",The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087982/),[ng] / [h·ml],53.3,90730,DB00422,Methylphenidate
,28087982,AUC,"Median AUC of d-methylphenidate was significantly larger in the group carrying the 143E allele (53.3 ng ml-1 h-1 , range 38.6-93.9) than in the control group (21.4 ng ml-1 h-1 , range 15.7-34.9) (P < 0.0001).",The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087982/),[ng] / [h·ml],21.4,90731,DB00422,Methylphenidate
,28087982,AUC,"Median AUC of d-methylphenidate was significantly larger in the group with four CES1 copies (34.5 ng ml-1 h-1 , range 21.3-62.8) than in the control group (P = 0.01) and the group with three CES1 copies (23.8 ng ml-1 h-1 , range 15.3-32.0, P = 0.03).",The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087982/),[ng] / [h·ml],34.5,90732,DB00422,Methylphenidate
,28087982,AUC,"Median AUC of d-methylphenidate was significantly larger in the group with four CES1 copies (34.5 ng ml-1 h-1 , range 21.3-62.8) than in the control group (P = 0.01) and the group with three CES1 copies (23.8 ng ml-1 h-1 , range 15.3-32.0, P = 0.03).",The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087982/),[ng] / [h·ml],23.8,90733,DB00422,Methylphenidate
,12537513,elimination half-life,"The elimination half-life is approximately 12-15 hours, which is largely reflective of the pharmacokinetics of the longer-lived l-enantiomer.",Clinical pharmacokinetic profile of modafinil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12537513/),h,12-15,99272,DB00422,Methylphenidate
,31786618,AUC,This subject also had the highest d-threo-methylphenidate AUC (191 ng*h/mL versus 32-119 ng*h/mL in the other subjects).,Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31786618/),[h·ng] / [ml],191,100955,DB00422,Methylphenidate
,31786618,AUC,This subject also had the highest d-threo-methylphenidate AUC (191 ng*h/mL versus 32-119 ng*h/mL in the other subjects).,Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31786618/),[h·ng] / [ml],32-119,100956,DB00422,Methylphenidate
,10761165,AUC,Mean methylphenidate AUC and terminal half-life were similar after single (32.9 ng.h/mL and 3.9 hours) and multiple doses (35.2 ng.h/mL and 3.9 hours) of OROS (methylphenidate HCl).,Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761165/),[h·ng] / [ml],32.9,112279,DB00422,Methylphenidate
,10761165,AUC,Mean methylphenidate AUC and terminal half-life were similar after single (32.9 ng.h/mL and 3.9 hours) and multiple doses (35.2 ng.h/mL and 3.9 hours) of OROS (methylphenidate HCl).,Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761165/),[h·ng] / [ml],35.2,112280,DB00422,Methylphenidate
,10761165,terminal half-life,Mean methylphenidate AUC and terminal half-life were similar after single (32.9 ng.h/mL and 3.9 hours) and multiple doses (35.2 ng.h/mL and 3.9 hours) of OROS (methylphenidate HCl).,Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761165/),h,3.9,112281,DB00422,Methylphenidate
,10761165,terminal half-life,Mean methylphenidate AUC and terminal half-life were similar after single (32.9 ng.h/mL and 3.9 hours) and multiple doses (35.2 ng.h/mL and 3.9 hours) of OROS (methylphenidate HCl).,Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761165/),[h·ng] / [ml],35.2,112282,DB00422,Methylphenidate
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,47,116256,DB00422,Methylphenidate
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,42,116257,DB00422,Methylphenidate
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,46,116258,DB00422,Methylphenidate
,9450511,ED50s,"The ED50s (50% occupancy of DAT by cocaine) were 0.27 and 0.17 mg/kg for [11C]d-threo-methylphenidate and [11C]cocaine, respectively.",Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],0.27,121660,DB00422,Methylphenidate
,9450511,ED50s,"The ED50s (50% occupancy of DAT by cocaine) were 0.27 and 0.17 mg/kg for [11C]d-threo-methylphenidate and [11C]cocaine, respectively.",Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],0.17,121661,DB00422,Methylphenidate
,9450511,ED50s,This is significantly lower than values obtained with labeled beta-CIT and other similar radiotracers with a slow uptake and clearance (ED50s: 3-7 mg/kg).,Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],3-7,121662,DB00422,Methylphenidate
,16789796,peak plasma concentrations,"In children with ADHD, MTS patches releasing MPH doses of 10-30 mg over a 9-hour period (12.5-37.5 cm2 patch size) is steadily absorbed, with mean peak plasma concentrations of d-MPH (20-46.5 ng/mL) reached in approximately 8 hours.",Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16789796/),[ng] / [ml],20-46.5,123979,DB00422,Methylphenidate
less,29681285,detection time,"The developed approach is particularly beneficial to PK studies for a very small sample volume (10 μL) is needed, the extraction time is as short as 3 min, and the detection time is less than 30 s.",Solid phase microextraction combined with thermal-desorption electrospray ionization mass spectrometry for high-throughput pharmacokinetics assays. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29681285/),s,30,125199,DB00422,Methylphenidate
,20535053,total MPH excreted,Mean total MPH excreted was 0.02 mg (about 0.08% of the administered dose).,Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20535053/),mg,0.02,128946,DB00422,Methylphenidate
,20535053,total MPH excreted,Mean total MPH excreted was 0.04 mg (about 0.18% of the administered dose).,Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20535053/),mg,0.04,128947,DB00422,Methylphenidate
,11587491,tmax,Dl-MPH-SR on average delayed tmax from 2.3 to 3.7 h and lowered Cmax 34%.,Effects of food on the pharmacokinetics of methylphenidate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11587491/),h,2.3,140321,DB00422,Methylphenidate
,11587491,tmax,Dl-MPH-SR on average delayed tmax from 2.3 to 3.7 h and lowered Cmax 34%.,Effects of food on the pharmacokinetics of methylphenidate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11587491/),h,3.7,140322,DB00422,Methylphenidate
,11587491,tmax,"After dl-MPH-IR, food delayed average tmax from 2.0 to 2.5 but had no effect on tmax after dl-MPH-SR.",Effects of food on the pharmacokinetics of methylphenidate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11587491/),,2.0,140323,DB00422,Methylphenidate
,11587491,tmax,"After dl-MPH-IR, food delayed average tmax from 2.0 to 2.5 but had no effect on tmax after dl-MPH-SR.",Effects of food on the pharmacokinetics of methylphenidate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11587491/),,2.5,140324,DB00422,Methylphenidate
,29039979,Cmax,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[ng] / [[mg·kg·ml]],9.1,157723,DB00422,Methylphenidate
,29039979,Cmax,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[ng] / [[mg·kg·ml]],8.8,157724,DB00422,Methylphenidate
,29039979,Cmax,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[ng] / [[mg·kg·ml]],7.4,157725,DB00422,Methylphenidate
,29039979,AUC0-t,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[h·ng] / [[mg·kg·ml]],126.5,157726,DB00422,Methylphenidate
,29039979,AUC0-t,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[h·ng] / [[mg·kg·ml]],129.4,157727,DB00422,Methylphenidate
,29039979,AUC0-t,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[h·ng] / [[mg·kg·ml]],129.7,157728,DB00422,Methylphenidate
,29039979,Tmax,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),h,15.6,157729,DB00422,Methylphenidate
,29039979,Tmax,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),h,17.1,157730,DB00422,Methylphenidate
,29039979,Tmax,"Mean values (coefficient of variation [CV]%) of weight-adjusted pharmacokinetic parameters were similar in adults and in adolescents and children with ADHD: Cmax ([ng/mL]/[mg/kg]) was 9.1 (35.2), 8.8 (34.5), and 7.4 (30.1); AUC0-t ([ng · h/mL]/[mg/kg]) was 126.5 (35.5), 129.4 (34.8), and 129.7 (27.3); and Tmax (hours) was 15.6 (11.1), 17.1 (14.5), and 17.7 (14.1), respectively.","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),h,17.7,157731,DB00422,Methylphenidate
,29039979,time to achieve ascending plasma MPH concentrations,"Intersubject variability in the mean time to achieve ascending plasma MPH concentrations of 2, 3, 4, and 5 ng/mL was low (CV: 7.8%-17.7%).","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[ng] / [ml],2,157732,DB00422,Methylphenidate
,29039979,time to achieve ascending plasma MPH concentrations,"Intersubject variability in the mean time to achieve ascending plasma MPH concentrations of 2, 3, 4, and 5 ng/mL was low (CV: 7.8%-17.7%).","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[ng] / [ml],3,157733,DB00422,Methylphenidate
,29039979,time to achieve ascending plasma MPH concentrations,"Intersubject variability in the mean time to achieve ascending plasma MPH concentrations of 2, 3, 4, and 5 ng/mL was low (CV: 7.8%-17.7%).","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[ng] / [ml],4,157734,DB00422,Methylphenidate
,29039979,time to achieve ascending plasma MPH concentrations,"Intersubject variability in the mean time to achieve ascending plasma MPH concentrations of 2, 3, 4, and 5 ng/mL was low (CV: 7.8%-17.7%).","Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29039979/),[ng] / [ml],5,157735,DB00422,Methylphenidate
,12657914,limits of detection,The limits of detection (0.01 microg/mL) and quantitation (0.5 microg/mL) were well below the concentration expected in serum from patients receiving therapeutic doses of modafinil.,Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657914/),[μg] / [ml],0.01,159323,DB00422,Methylphenidate
,6410043,maximal concentration,The mean (+/-S.E.) maximal concentration in plasma for MPH was 3.5 +/- 0.4 ng/ml after 0.15 mg/kg and 7.8 +/- 0.8 ng/ml after 0.3 mg/kg.,"Pharmacokinetics of methylphenidate in man, rat and monkey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6410043/),[ng] / [ml],3.5,161851,DB00422,Methylphenidate
,6410043,maximal concentration,The mean (+/-S.E.) maximal concentration in plasma for MPH was 3.5 +/- 0.4 ng/ml after 0.15 mg/kg and 7.8 +/- 0.8 ng/ml after 0.3 mg/kg.,"Pharmacokinetics of methylphenidate in man, rat and monkey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6410043/),[ng] / [ml],7.8,161852,DB00422,Methylphenidate
,6410043,clearances,MPH clearances were high (10.1 liters/hr/kg) and variable (range: 3.6-23.2) for the 0.3 mg/kg dose.,"Pharmacokinetics of methylphenidate in man, rat and monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6410043/),[l] / [h·kg],10.1,161853,DB00422,Methylphenidate
,6410043,absolute bioavailability,"The absolute bioavailability of MPH was found to be 0.19 in the rat and 0.22 in the monkey, suggesting substantial presystemic elimination of MPH.","Pharmacokinetics of methylphenidate in man, rat and monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6410043/),,0.19,161854,DB00422,Methylphenidate
,6410043,absolute bioavailability,"The absolute bioavailability of MPH was found to be 0.19 in the rat and 0.22 in the monkey, suggesting substantial presystemic elimination of MPH.","Pharmacokinetics of methylphenidate in man, rat and monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6410043/),,0.22,161855,DB00422,Methylphenidate
,7258793,apparent alpha half-life,"In horses given (rapid IV) methylphenidate (Ritalin, alpha-phenyl-2-piperidinacetic acid methyl ester; 0.70 mg/kg), plasma concentrations of the drug decreased rapidly at first, with an apparent alpha half-life of about 19 minutes, and then more slowly, with an apparent beta half-life of about 2.4 hours.",Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7258793/),min,19,162023,DB00422,Methylphenidate
,7258793,apparent beta half-life,"In horses given (rapid IV) methylphenidate (Ritalin, alpha-phenyl-2-piperidinacetic acid methyl ester; 0.70 mg/kg), plasma concentrations of the drug decreased rapidly at first, with an apparent alpha half-life of about 19 minutes, and then more slowly, with an apparent beta half-life of about 2.4 hours.",Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7258793/),h,2.4,162024,DB00422,Methylphenidate
,7258793,Urinary clearance time,"Urinary clearance time, however, was longer, and between 12 and 24 hours should be allowed for a dose of methylphenidate to ""clear"" from urine.",Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7258793/),h,12 and 24,162025,DB00422,Methylphenidate
,20096514,Oral fluid peak concentrations,Oral fluid peak concentrations of MPH ranged between 13.5 and 30.9 ng/mL at 3.0 h after drug intake.,Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20096514/),[ng] / [ml],13.5 and 30.9,166107,DB00422,Methylphenidate
,20096514,Oral fluid-to-plasma MPH ratio,Oral fluid-to-plasma MPH ratio between 13.1 and 3.2 demonstrated an accumulation of the drug in oral fluid.,Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20096514/),,13.1 and 3.2,166108,DB00422,Methylphenidate
,20096514,peak concentration,"Conversely, RA was found in oral fluid at peak concentration (23.4-62.9 ng/mL) equivalent to one-tenth of those found in plasma.",Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20096514/),[ng] / [ml],23.4-62.9,166109,DB00422,Methylphenidate
,8436161,terminal half-life,"In the patient the oral clearance (CL/f) of (+)-methylphenidate fell 3-fold and the area under the concentration-time curve (AUC) rose 7-fold when the dose was increased from 20 to 40 mg (from 0.27 to 0.53 mg.kg-1), in spite of the relatively constant terminal half-life of 2.6-2.7 h.",Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436161/),h,2.6-2.7,166823,DB00422,Methylphenidate
,17339864,maximum d-MPH plasma concentration (C(max),"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ng] / [ml],15.3,169815,DB00422,Methylphenidate
,17339864,maximum d-MPH plasma concentration (C(max),"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ng] / [ml],21.5,169816,DB00422,Methylphenidate
,17339864,maximum d-MPH plasma concentration (C(max),"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ng] / [ml],21.4,169817,DB00422,Methylphenidate
,17339864,area under the concentration-time curve,"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ml·ng] / [h],82.9,169818,DB00422,Methylphenidate
,17339864,area under the concentration-time curve,"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),,105.2,169819,DB00422,Methylphenidate
,17339864,area under the concentration-time curve,"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ml·ng] / [h],102.9,169820,DB00422,Methylphenidate
,10786896,recoveries,"The method responses are linear over the range of plasma concentrations of MP and RA observed in monkeys, gives respective analyte recoveries of 75 and 60% with reasonable precision and accuracy, and demonstrates robust MS performance for rapid determination of MP/RA plasma levels.",Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10786896/),%,75,173446,DB00422,Methylphenidate
,10786896,recoveries,"The method responses are linear over the range of plasma concentrations of MP and RA observed in monkeys, gives respective analyte recoveries of 75 and 60% with reasonable precision and accuracy, and demonstrates robust MS performance for rapid determination of MP/RA plasma levels.",Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10786896/),%,60,173447,DB00422,Methylphenidate
,10786896,peak MP concentration,"The average peak MP concentration (ca. 16 ng/mL) and half-lives for MP and RA elimination in monkeys (1.79 and 2.31 h, respectively) were not significantly different under acute vs. chronic dosing conditions and were comparable to values previously reported from human studies.",Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10786896/),[ng] / [ml],16,173448,DB00422,Methylphenidate
,10786896,half-lives,"The average peak MP concentration (ca. 16 ng/mL) and half-lives for MP and RA elimination in monkeys (1.79 and 2.31 h, respectively) were not significantly different under acute vs. chronic dosing conditions and were comparable to values previously reported from human studies.",Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10786896/),h,1.79,173449,DB00422,Methylphenidate
,10786896,half-lives,"The average peak MP concentration (ca. 16 ng/mL) and half-lives for MP and RA elimination in monkeys (1.79 and 2.31 h, respectively) were not significantly different under acute vs. chronic dosing conditions and were comparable to values previously reported from human studies.",Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatography/electrospray ionization mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10786896/),h,2.31,173450,DB00422,Methylphenidate
,20454855,relative bioavailability,The relative bioavailability of the SR formulation was 30.58 +/- 13.73%.,Pharmacokinetics of methylphenidate following two oral formulations (immediate and sustained release) in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20454855/),%,30.58,179222,DB00422,Methylphenidate
,27021606,Cmax,"Mean Cmax for MPH ERCT and IR MPH was 12.51 ng/mL and 15.57 ng/mL, respectively; mean time to Cmax was 4.16 hours and 6.43 hours, respectively.",Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27021606/),[ng] / [ml],12.51,191741,DB00422,Methylphenidate
,27021606,Cmax,"Mean Cmax for MPH ERCT and IR MPH was 12.51 ng/mL and 15.57 ng/mL, respectively; mean time to Cmax was 4.16 hours and 6.43 hours, respectively.",Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27021606/),[ng] / [ml],15.57,191742,DB00422,Methylphenidate
,27021606,time to Cmax,"Mean Cmax for MPH ERCT and IR MPH was 12.51 ng/mL and 15.57 ng/mL, respectively; mean time to Cmax was 4.16 hours and 6.43 hours, respectively.",Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27021606/),h,4.16,191743,DB00422,Methylphenidate
,27021606,time to Cmax,"Mean Cmax for MPH ERCT and IR MPH was 12.51 ng/mL and 15.57 ng/mL, respectively; mean time to Cmax was 4.16 hours and 6.43 hours, respectively.",Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27021606/),h,6.43,191744,DB00422,Methylphenidate
,7839313,t1/2,"dl-threo-Methylphenidate (Ritalin) was labeled with carbon-11 (t1/2:20.4 minutes) in order to measure its pharmacokinetics, to evaluate it as a radiotracer for the presynaptic dopaminergic neuron, and to examine its sensitivity to the loss of dopaminergic neurons.",Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),min,20.4,192690,DB00422,Methylphenidate
,7839313,Peak uptake,Peak uptake (0.04%/cc) occurred at 5-15 minutes post-injection.,Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),[%] / [cc],0.04,192691,DB00422,Methylphenidate
,7839313,half-time for clearance from peak uptake,The half-time for clearance from peak uptake for [11C]MP was 60 minutes and the ratio between the radioactivity in the striatum and that in the cerebellum (ST/CB) ranged from 2.2 to 2.6 at 40 minutes.,Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),min,60,192692,DB00422,Methylphenidate
,30169917,half-maximal inhibitory concentration (IC50 ),"The half-maximal inhibitory concentration (IC50 ) values of chenodeoxycholate and taurocholate were 13.55 and 19.51 μM, respectively, consistent with a physiological significance.",Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169917/),μM,13.55,194874,DB00422,Methylphenidate
,30169917,half-maximal inhibitory concentration (IC50 ),"The half-maximal inhibitory concentration (IC50 ) values of chenodeoxycholate and taurocholate were 13.55 and 19.51 μM, respectively, consistent with a physiological significance.",Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169917/),μM,19.51,194875,DB00422,Methylphenidate
,11028253,AUCinf,"Mean AUCinf values for d-methylphenidate were 42.2, 80.9, and 120 ng.h/mL for the 18, 36, and 54 mg doses, respectively, increasing dose proportionally.","Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028253/),[h·ng] / [ml],42.2,195612,DB00422,Methylphenidate
,11028253,AUCinf,"Mean AUCinf values for d-methylphenidate were 42.2, 80.9, and 120 ng.h/mL for the 18, 36, and 54 mg doses, respectively, increasing dose proportionally.","Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028253/),[h·ng] / [ml],80.9,195613,DB00422,Methylphenidate
,11028253,AUCinf,"Mean AUCinf values for d-methylphenidate were 42.2, 80.9, and 120 ng.h/mL for the 18, 36, and 54 mg doses, respectively, increasing dose proportionally.","Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028253/),[h·ng] / [ml],120,195614,DB00422,Methylphenidate
,11028253,AUCinf,"AUCinf values for l-methylphenidate were only approximately 1% of d-methylphenidate (0.43, 0.96, and 1.82 ng.h/mL for the 18, 36, and 54 mg dose groups, respectively).","Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028253/),[h·ng] / [ml],0.43,195615,DB00422,Methylphenidate
,11028253,AUCinf,"AUCinf values for l-methylphenidate were only approximately 1% of d-methylphenidate (0.43, 0.96, and 1.82 ng.h/mL for the 18, 36, and 54 mg dose groups, respectively).","Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028253/),[h·ng] / [ml],0.96,195616,DB00422,Methylphenidate
,11028253,AUCinf,"AUCinf values for l-methylphenidate were only approximately 1% of d-methylphenidate (0.43, 0.96, and 1.82 ng.h/mL for the 18, 36, and 54 mg dose groups, respectively).","Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028253/),[h·ng] / [ml],1.82,195617,DB00422,Methylphenidate
,30810347,relative bioavailability,The relative bioavailability for DR/ER-MPH compared to IR MPH was 73.9%.,"Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30810347/),%,73.9,196941,DB00422,Methylphenidate
,18184535,Cmax,"The three formulations had Cmax and AUC0-infinity values of 15.5 +/- 4.3 ng/ml and 119 +/- 41 ng x h/ml for bimodal release d-MPH, 17.9 +/- 5.3 ng/ml and 115 +/- 40 ng A h/ml for immediate release d-MPH, and 16.4 +/- 4.4 ng/ml and 122 +/- 36 ng x h/ml for d,l-MPH bimodal release, respectively.","Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184535/),[ng] / [ml],15.5,198120,DB00422,Methylphenidate
,18184535,Cmax,"The three formulations had Cmax and AUC0-infinity values of 15.5 +/- 4.3 ng/ml and 119 +/- 41 ng x h/ml for bimodal release d-MPH, 17.9 +/- 5.3 ng/ml and 115 +/- 40 ng A h/ml for immediate release d-MPH, and 16.4 +/- 4.4 ng/ml and 122 +/- 36 ng x h/ml for d,l-MPH bimodal release, respectively.","Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184535/),[ng] / [ml],17.9,198121,DB00422,Methylphenidate
,18184535,Cmax,"The three formulations had Cmax and AUC0-infinity values of 15.5 +/- 4.3 ng/ml and 119 +/- 41 ng x h/ml for bimodal release d-MPH, 17.9 +/- 5.3 ng/ml and 115 +/- 40 ng A h/ml for immediate release d-MPH, and 16.4 +/- 4.4 ng/ml and 122 +/- 36 ng x h/ml for d,l-MPH bimodal release, respectively.","Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184535/),[ng] / [ml],16.4,198122,DB00422,Methylphenidate
,18184535,AUC0-infinity,"The three formulations had Cmax and AUC0-infinity values of 15.5 +/- 4.3 ng/ml and 119 +/- 41 ng x h/ml for bimodal release d-MPH, 17.9 +/- 5.3 ng/ml and 115 +/- 40 ng A h/ml for immediate release d-MPH, and 16.4 +/- 4.4 ng/ml and 122 +/- 36 ng x h/ml for d,l-MPH bimodal release, respectively.","Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184535/),[h·ng] / [ml],119,198123,DB00422,Methylphenidate
,18184535,AUC0-infinity,"The three formulations had Cmax and AUC0-infinity values of 15.5 +/- 4.3 ng/ml and 119 +/- 41 ng x h/ml for bimodal release d-MPH, 17.9 +/- 5.3 ng/ml and 115 +/- 40 ng A h/ml for immediate release d-MPH, and 16.4 +/- 4.4 ng/ml and 122 +/- 36 ng x h/ml for d,l-MPH bimodal release, respectively.","Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184535/),[ng] / [ml],16.4,198124,DB00422,Methylphenidate
,18184535,AUC0-infinity,"The three formulations had Cmax and AUC0-infinity values of 15.5 +/- 4.3 ng/ml and 119 +/- 41 ng x h/ml for bimodal release d-MPH, 17.9 +/- 5.3 ng/ml and 115 +/- 40 ng A h/ml for immediate release d-MPH, and 16.4 +/- 4.4 ng/ml and 122 +/- 36 ng x h/ml for d,l-MPH bimodal release, respectively.","Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18184535/),[h·ng] / [ml],122,198125,DB00422,Methylphenidate
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,3.25,211606,DB00422,Methylphenidate
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,6.05,211607,DB00422,Methylphenidate
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,12.6,211608,DB00422,Methylphenidate
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,18.5,211609,DB00422,Methylphenidate
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),[ng] / [ml],25.2,211610,DB00422,Methylphenidate
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,3.18,211611,DB00422,Methylphenidate
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,5.84,211612,DB00422,Methylphenidate
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),%,12.5,211613,DB00422,Methylphenidate
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,17.7,211614,DB00422,Methylphenidate
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),[ng] / [ml],23.6,211615,DB00422,Methylphenidate
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,24.3,211616,DB00422,Methylphenidate
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,45.9,211617,DB00422,Methylphenidate
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,96.4,211618,DB00422,Methylphenidate
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,144,211619,DB00422,Methylphenidate
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),[h·ng] / [ml],195,211620,DB00422,Methylphenidate
,20607239,MTD,DLTs of reversible grade 3 benzodiazepine-like effects defined the estimated MTD of 60 mg QID/M for 14 days.,"Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20607239/),,60,212039,DB00422,Methylphenidate
,20607239,terminal half-life,"MLN8054 was absorbed rapidly, exposure was dose proportional, and terminal half-life was 30-40 h.","Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20607239/),h,30-40,212040,DB00422,Methylphenidate
,26794682,tmax,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,10-12,213346,DB00422,Methylphenidate
,26794682,elimination (t1/2,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,47-77,213347,DB00422,Methylphenidate
,18759645,plasma concentrations,"Over the time-course of clinical effectiveness (2-12 h), mean plasma concentrations of d-MPH at the most frequently titrated doses (15 and 20 mg/9 h) ranged from 4.97 to 28.3 ng/mL.",Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18759645/),[ng] / [ml],4.97 to 28.3,219503,DB00422,Methylphenidate
,2706316,peak MPH concentration,The mean peak MPH concentration was 6.4 ng ml-1 for the IR product versus 4.6 ng ml-1 and 4.8 ng ml-1 for the two SR formulations.,The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706316/),[ng] / [ml],6.4,221411,DB00422,Methylphenidate
,2706316,peak MPH concentration,The mean peak MPH concentration was 6.4 ng ml-1 for the IR product versus 4.6 ng ml-1 and 4.8 ng ml-1 for the two SR formulations.,The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706316/),[ng] / [ml],4.6,221412,DB00422,Methylphenidate
,2706316,peak MPH concentration,The mean peak MPH concentration was 6.4 ng ml-1 for the IR product versus 4.6 ng ml-1 and 4.8 ng ml-1 for the two SR formulations.,The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706316/),[ng] / [ml],4.8,221413,DB00422,Methylphenidate
,10434228,t1/2,"Iterated solutions of best fit were: t1/2, 4.5 hours (95% confidence interval [CI]: 3.1-8.1 hours), and apparent clearance, 90.7 ml/min/kg (95% CI: 74.6-106.7 ml/min/kg).",Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434228/),h,4.5,222362,DB00422,Methylphenidate
,10434228,apparent clearance,"Iterated solutions of best fit were: t1/2, 4.5 hours (95% confidence interval [CI]: 3.1-8.1 hours), and apparent clearance, 90.7 ml/min/kg (95% CI: 74.6-106.7 ml/min/kg).",Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434228/),[ml] / [kg·min],90.7,222363,DB00422,Methylphenidate
,19954715,AUC0-t,Geometric means +/- SD for AUC0-t and Cmax were 35.5 +/- 10.1 ng x h/ml and 4.05 +/- 0.96 ng/ml (Equasym Retard) and 39.2 +/- 13.8 ng x h/ml and 5.26 +/- 2.11 ng/ml (Medikinet retard).,Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954715/),[h·ng] / [ml],35.5,223446,DB00422,Methylphenidate
,19954715,AUC0-t,Geometric means +/- SD for AUC0-t and Cmax were 35.5 +/- 10.1 ng x h/ml and 4.05 +/- 0.96 ng/ml (Equasym Retard) and 39.2 +/- 13.8 ng x h/ml and 5.26 +/- 2.11 ng/ml (Medikinet retard).,Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954715/),[h·ng] / [ml],39.2,223447,DB00422,Methylphenidate
,19954715,Cmax,Geometric means +/- SD for AUC0-t and Cmax were 35.5 +/- 10.1 ng x h/ml and 4.05 +/- 0.96 ng/ml (Equasym Retard) and 39.2 +/- 13.8 ng x h/ml and 5.26 +/- 2.11 ng/ml (Medikinet retard).,Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954715/),[ng] / [ml],4.05,223448,DB00422,Methylphenidate
,19954715,Cmax,Geometric means +/- SD for AUC0-t and Cmax were 35.5 +/- 10.1 ng x h/ml and 4.05 +/- 0.96 ng/ml (Equasym Retard) and 39.2 +/- 13.8 ng x h/ml and 5.26 +/- 2.11 ng/ml (Medikinet retard).,Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954715/),[ng] / [ml],5.26,223449,DB00422,Methylphenidate
,20696604,relative bioavailability,"The relative bioavailability of the SR formulation was 30.58±13.73% and, despite low drug plasma concentrations, the SR formulation resulted in uniform plasma concentrations of d,l-MPH.",Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20696604/),%,30.58,229480,DB00422,Methylphenidate
,8430051,absolute bioavailability (F),"After oral administration of dl-MPH, the absolute bioavailability (F) of d-MPH was 0.23 and that of l-MPH was 0.05.",Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430051/),,0.23,230568,DB00422,Methylphenidate
,8430051,absolute bioavailability (F),"After oral administration of dl-MPH, the absolute bioavailability (F) of d-MPH was 0.23 and that of l-MPH was 0.05.",Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430051/),,0.05,230569,DB00422,Methylphenidate
∼,25019201,tmax,"The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose.",A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019201/),h,2,231162,DB00422,Methylphenidate
,25019201,plasma t1/2,"The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose.",A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019201/),h,4 - 6,231163,DB00422,Methylphenidate
,20167695,Oral fluid concentrations,Oral fluid concentrations of MPH ranged between 0.5 and 466.7 microg/L and peaked at 0.5 h after administration of the fast-release formulation; they ranged between 0.7 and 89.5 microg/L and peaked at 2 h after administration of the extended-release formulation.,Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167695/),[μg] / [l],0.5 and 466.7,234539,DB00422,Methylphenidate
,20167695,Oral fluid concentrations,Oral fluid concentrations of MPH ranged between 0.5 and 466.7 microg/L and peaked at 0.5 h after administration of the fast-release formulation; they ranged between 0.7 and 89.5 microg/L and peaked at 2 h after administration of the extended-release formulation.,Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167695/),[μg] / [l],0.7 and 89.5,234540,DB00422,Methylphenidate
,20167695,OF/P ratio,"Both formulations presented bimodal time-course curves for the OF/P ratio, ranging between 1.8 and 242.1 for the fast-release formulation and between 2.6 and 27.0 for extended-release.",Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167695/),,1.8 and 242.1,234541,DB00422,Methylphenidate
,20167695,OF/P ratio,"Both formulations presented bimodal time-course curves for the OF/P ratio, ranging between 1.8 and 242.1 for the fast-release formulation and between 2.6 and 27.0 for extended-release.",Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167695/),,2.6 and 27.0,234542,DB00422,Methylphenidate
,8143392,elimination half-life,"The elimination half-life of (+)-methylphenidate in patients was within the range of 2.6 to 3 hours, and the time to reach the peak concentration ranged from 1 to 3 hours.",Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8143392/),h,2.6 to 3,236532,DB00422,Methylphenidate
,8143392,time to reach the peak concentration,"The elimination half-life of (+)-methylphenidate in patients was within the range of 2.6 to 3 hours, and the time to reach the peak concentration ranged from 1 to 3 hours.",Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8143392/),h,1 to 3,236533,DB00422,Methylphenidate
more,8143392,sleep latency,The sleep latency of more than 10 minutes was achieved by maintaining the plasma (+)-methylphenidate concentrations above 3 ng/ml.,Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8143392/),min,10,236534,DB00422,Methylphenidate
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,10.1,237702,DB00422,Methylphenidate
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,10.5,237703,DB00422,Methylphenidate
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,7.5,237704,DB00422,Methylphenidate
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,7.0,237705,DB00422,Methylphenidate
,10205632,plasma half-life,Methylphenidate has a short plasma half-life (1-2 h) and thus needs to be frequently administered for effective therapy.,Transdermal iontophoretic delivery of methylphenidate HCl in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10205632/),h,1-2,248162,DB00422,Methylphenidate
,10205632,maximum flux,A maximum flux of 12.0 micrograms/(cm2 h) of protonated methylphenidate was estimated from the passive transport data at pH 3.5.,Transdermal iontophoretic delivery of methylphenidate HCl in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10205632/),[μg] / [cm2·h],12.0,248163,DB00422,Methylphenidate
,10205632,efficiency,"From the present experiments, the efficiency of iontophoretic delivery of methylphenidate was approximately 700 micrograms/(mA h).",Transdermal iontophoretic delivery of methylphenidate HCl in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10205632/),[μg] / [h·ma],700,248164,DB00422,Methylphenidate
,10205632,minimum transport area,"Based on in vitro skin flux data, the daily dose of 15-40 mg methylphenidate can be achieved using a current density of 0.5 mA/cm2 and a minimum transport area of 2-5 cm2 for 24-h application, or an area of 4-10 cm2 for 12-h (daytime) application.",Transdermal iontophoretic delivery of methylphenidate HCl in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10205632/),cm2,2-5,248165,DB00422,Methylphenidate
,10205632,mobility,"From methylphenidate skin flux values, methylphenidate mobility of 2.2 x 10(-4) cm2/(V s) was estimated, which compares reasonably with its free solution mobility of 6.6 x 10(-4) cm2/(V s).",Transdermal iontophoretic delivery of methylphenidate HCl in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10205632/),[cm2] / [s·v],2.2 x 10(-4),248166,DB00422,Methylphenidate
,10205632,mobility,"From methylphenidate skin flux values, methylphenidate mobility of 2.2 x 10(-4) cm2/(V s) was estimated, which compares reasonably with its free solution mobility of 6.6 x 10(-4) cm2/(V s).",Transdermal iontophoretic delivery of methylphenidate HCl in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10205632/),[cm2] / [s·v],6.6 x 10(-4),248167,DB00422,Methylphenidate
,12648029,initial peak plasma concentration,"The Ritalin LA formulation displayed a distinctly biphasic pharmacokinetic profile, with mean initial peak plasma concentration of 7 microg/L at an average of 2.1 hours after administration and a second peak of 9.3 microg/L occurring at 5.6 hours.",Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648029/),[μg] / [l],7,249314,DB00422,Methylphenidate
,12648029,initial plateau concentration,"In contrast, the profile of the Concerta formulation rapidly reached an initial plateau concentration of 3.4 microg/L at 3.3 hours after administration and a second mean plateau concentration of 5.9 microg/L approximately 6 hours after administration.",Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648029/),[μg] / [l],3.4,249315,DB00422,Methylphenidate
,12648029,plateau concentration,"In contrast, the profile of the Concerta formulation rapidly reached an initial plateau concentration of 3.4 microg/L at 3.3 hours after administration and a second mean plateau concentration of 5.9 microg/L approximately 6 hours after administration.",Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648029/),[μg] / [l],5.9,249316,DB00422,Methylphenidate
,12648029,AUC(4),Substantially more MPH was absorbed from Ritalin LA than from Concert over the first 4 hours; the respective AUC(4) values were 18.5 and 9.3 microg x h/L (p < 0.001).,Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648029/),[h·μg] / [l],18.5,249317,DB00422,Methylphenidate
,12648029,AUC(4),Substantially more MPH was absorbed from Ritalin LA than from Concert over the first 4 hours; the respective AUC(4) values were 18.5 and 9.3 microg x h/L (p < 0.001).,Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648029/),[h·μg] / [l],9.3,249318,DB00422,Methylphenidate
,17804308,lambda(ex),"MPH was derivatized using DIB-Cl, and separated isocratically on a C18 column using a HPLC system with fluorescence detection (lambda(ex)=330 nm, lambda(em)=460 nm).",A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17804308/),,330,250504,DB00422,Methylphenidate
,17804308,lambda(em),"MPH was derivatized using DIB-Cl, and separated isocratically on a C18 column using a HPLC system with fluorescence detection (lambda(ex)=330 nm, lambda(em)=460 nm).",A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17804308/),,460,250505,DB00422,Methylphenidate
,25274428,Maximum concentration,Maximum concentration was lower for MPH-MLR 80 mg than IR methylphenidate 25 mg three times daily on day 1 (23.70 vs. 31.47 ng/mL); exposure was similar.,Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25274428/),[ng] / [ml],23.70,252968,DB00422,Methylphenidate
,25274428,Maximum concentration,Maximum concentration was lower for MPH-MLR 80 mg than IR methylphenidate 25 mg three times daily on day 1 (23.70 vs. 31.47 ng/mL); exposure was similar.,Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25274428/),[ng] / [ml],31.47,252969,DB00422,Methylphenidate
,25274428,area under the plasma drug concentration vs. time curve from 0 to 4 h,"The mean ± SD MPH-MLR 80-mg capsule day 4 area under the plasma drug concentration vs. time curve from 0 to 4 h (74.5 ± 15.2 ng·h/mL) was greater than IR methylphenidate 25 mg three times daily (66.0 ± 17.4 ng·h/mL), confirming steady-state levels during the study period.",Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25274428/),[h·ng] / [ml],74.5,252970,DB00422,Methylphenidate
,25274428,area under the plasma drug concentration vs. time curve from 0 to 4 h,"The mean ± SD MPH-MLR 80-mg capsule day 4 area under the plasma drug concentration vs. time curve from 0 to 4 h (74.5 ± 15.2 ng·h/mL) was greater than IR methylphenidate 25 mg three times daily (66.0 ± 17.4 ng·h/mL), confirming steady-state levels during the study period.",Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25274428/),[h·ng] / [ml],66.0,252971,DB00422,Methylphenidate
,9337434,percent dissolution,"At this time point, the percent dissolution of the whole versus halved tablets was 57% versus 74% (Ritalin-SR), respectively, and 49% versus 67% (generic), respectively.",Effect on dissolution from halving methylphenidate extended-release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337434/),%,57,253813,DB00422,Methylphenidate
,9337434,percent dissolution,"At this time point, the percent dissolution of the whole versus halved tablets was 57% versus 74% (Ritalin-SR), respectively, and 49% versus 67% (generic), respectively.",Effect on dissolution from halving methylphenidate extended-release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337434/),%,74,253814,DB00422,Methylphenidate
,9337434,percent dissolution,"At this time point, the percent dissolution of the whole versus halved tablets was 57% versus 74% (Ritalin-SR), respectively, and 49% versus 67% (generic), respectively.",Effect on dissolution from halving methylphenidate extended-release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337434/),%,49,253815,DB00422,Methylphenidate
,9337434,percent dissolution,"At this time point, the percent dissolution of the whole versus halved tablets was 57% versus 74% (Ritalin-SR), respectively, and 49% versus 67% (generic), respectively.",Effect on dissolution from halving methylphenidate extended-release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337434/),%,67,253816,DB00422,Methylphenidate
,20861586,AUC0-∞,"The AUC0-∞ of d-MPH for NWP06 and IR MPH were 143.65 and 153.31 ng-hr/mL, respectively.","The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20861586/),[ng-hr] / [ml],143.65,260145,DB00422,Methylphenidate
,20861586,AUC0-∞,"The AUC0-∞ of d-MPH for NWP06 and IR MPH were 143.65 and 153.31 ng-hr/mL, respectively.","The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20861586/),[ng-hr] / [ml],153.31,260146,DB00422,Methylphenidate
,20861586,"peak plasma concentration, Cmax","The peak plasma concentration, Cmax (ng/mL), was 13.61 for NWP06 and 20.94 for IR MPH.","The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20861586/),[ng] / [ml],13.61,260147,DB00422,Methylphenidate
,20861586,"peak plasma concentration, Cmax","The peak plasma concentration, Cmax (ng/mL), was 13.61 for NWP06 and 20.94 for IR MPH.","The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20861586/),[ng] / [ml],20.94,260148,DB00422,Methylphenidate
,20861586,half-life,The half-life of NWP06 was 5.65 hours and Tmax was 5 hours.,"The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20861586/),h,5.65,260149,DB00422,Methylphenidate
,20861586,Tmax,The half-life of NWP06 was 5.65 hours and Tmax was 5 hours.,"The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20861586/),h,5,260150,DB00422,Methylphenidate
,20861586,half-life,"For IR MPH, the half-life was 3.74 hours and Tmax was 7.33 hours.","The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20861586/),h,3.74,260151,DB00422,Methylphenidate
,20861586,Tmax,"For IR MPH, the half-life was 3.74 hours and Tmax was 7.33 hours.","The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20861586/),h,7.33,260152,DB00422,Methylphenidate
,29863895,flow rate,"Chromatographic separation was achieved on a Zorbax C18 column using an isocratic mobile phase composed of acetonitrile and 5 mM ammonium formate buffer (20:80, v/v) at a flow rate of 0.5 ml/min.",Novel and rapid LC-MS/MS method for quantitative analysis of methylphenidate in dried blood spots. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29863895/),[ml] / [min],0.5,265449,DB00422,Methylphenidate
,7771915,uptake,"The uptake of [11C]methylphenidate in the brain was high (mean +/- SD, 7.5% +/- 1.5%), and the maximal concentration occurred in striatum.",Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7771915/),%,7.5,268333,DB00422,Methylphenidate
,7771915,Clearance,Clearance of [11C]methylphenidate from striatum (90 minutes) was significantly slower than that of [11C]cocaine (20 minutes).,Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7771915/),min,90,268334,DB00422,Methylphenidate
,7771915,Clearance,Clearance of [11C]methylphenidate from striatum (90 minutes) was significantly slower than that of [11C]cocaine (20 minutes).,Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7771915/),min,20,268335,DB00422,Methylphenidate
